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Abstract
Fast-scan cyclic voltammetry at carbon fiber microelectrodes allows rapid (sub-second) measurements of dopamine release
in behaving animals. Herein, we report the modification of existing technology and demonstrate the feasibility of making
sub-second measurements of dopamine release in the caudate nucleus of a human subject during brain surgery. First, we
describe the modification of our electrodes that allow for measurements to be made in a human brain. Next, we
demonstrate in vitro and in vivo, that our modified electrodes can measure stimulated dopamine release in a rat brain
equivalently to previously determined rodent electrodes. Finally, we demonstrate acute measurements of dopamine release
in the caudate of a human patient during DBS electrode implantation surgery. The data generated are highly amenable for
future work investigating the relationship between dopamine levels and important decision variables in human decision-
making tasks.
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Introduction
The neurotransmitter dopamine has been implicated in both
motoric and cognitive functions, especially those associated with
reward valuation processes [1–3]. Computational models of
dopamine function have been validated at the level of single unit
activity in non-human primates and rodents [4–7]. Recent
advances in neurochemical monitoring have enabled sub-second
dopamine detection in rodents during behavioral tasks [8,9],
providing the capacity for computational testing at the level of
dopamine release [10]. Nevertheless, in vivo measurements of
extracellular dopamine in human brains are currently restricted to
timescales afforded by microdialysis [11] or imaging [12] methods
that do not resolve sub-second computations mediated by
dopamine release. However, the now routine surgical implantation
of neuroprosthetic devices for deep-brain stimulation (DBS) in the
treatment of Parkinson’s disease [13] provides a window of
opportunity for unprecedented monitoring of neurotransmission in
the human brain using invasive electrode-based techniques [14].
Here, we describe the use of proven fast-scan cyclic voltammetry
methods for detecting dopamine [8,9] and the modification of
existing biocompatible electrodes [15] for use in human brain; we
demonstrate the feasibility of sub-second dopamine detection in
human striatum, and discuss the potential of pairing this kind of
measurement with human-decision making paradigms designed
around current computational models of dopamine function [16].
This advance provides a mechanism for studying long-standing
questions regarding dopamine’s role in human cognition by
permitting sub-second dopamine measurements in the human
brain during behavioral tasks.
Results and Discussion
In developing instrumentation to detect dopamine in the human
brain, we had three important criteria. The experimental
methodology must be safe to the patient, compatible with existing
neurosurgical apparatus and the operating-room environment,
and capable of sub-second detection of physiological dopamine.
To achieve these goals, we fabricated an electrode assembly for use
with clinical stereotactic apparatus, based upon an existing
biocompatible microsensor that has been validated for in vivo
dopamine detection [15]. Intraoperative electrophysiology elec-
trodes that are used for functional mapping during DBS-electrode
implantation are 276.5-mm long, 360-mm in diameter and housed
in a stainless-steel protective tube (Differential microTargetingTM
electrode, FHC). Therefore, we constructed electrode assemblies
to match these dimensions and housed them in identical protective
tubes (Figure 1a; see Methods S1). First, a carbon fiber (7-mm
diameter) was inserted into a fused silica tube (90-mm outer
diameter, 20-mm long) and sealed as previously described [15].
This capillary was then fixed into a larger-diameter (360 mm)
fused-silica capillary (271.5-mm long) leaving 5 mm exposed. Due
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Figure 1. Human-compatible carbon fiber microelectrode can detect dopamine in human striatum. (a) Human electrode assembly
comprised of protective tube with reference electrode at the tip (1), large-gauge fused silica capillary (2), small-gauge fused silica (3) and carbon fiber
(4). (b) Average change in peak oxidative current in rat striatum following electrical stimulation (60 Hz, 120 pulses, 300 mA) of dopamine axon
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to the relatively high electrical impedance of graphite (compared
to metal wires), the carbon fiber is not suitable for conducting the
signal along an electrode of this length while maintaining high-
fidelity electrochemical recordings. Therefore, a silver wire within
the larger capillary was used to bridge the back end of the capillary
with the sensor, connecting to the carbon fiber with silver
conductive paint. The electrode was then back loaded into a
polyimide-coated, stainless-steel protective tube (FHC) which has
1 mm of stainless steel exposed at the tip for use as a reference
electrode [17,18]. Finally, a gold-plated pin connector was
attached to the back end of the large capillary making electrical
contact with the silver wire via conductive epoxy, and heat-shrink
tubing was placed over the body of the connector, extending
5 mm along the fused-silica shaft.
The carbon-fiber sensor used in our electrode assembly is
identical to that used for previous applications [9,10,15], thus
shares the same electrochemical properties. Indeed, performance
of this assembly (with stainless-steel reference) for in vivo detection
of dopamine transmission was highly conserved relative to the
conventional glass-insulated carbon-fiber recording electrode
referenced to Ag/AgCl (n = 3 of each electrode type; Figure 1b).
Specifically, detection of stimulated dopamine release in the rat
produced responses that were similar in chemical identity
(r2 = 0.89, p,0.0001; Figure 1b inset), temporal response
(r2 = 0.95, p,0.0001; Figure 1b), and sensitivity (regression line
slope = 0.981). Using fast-scan cyclic voltammetry, we tested the
sensitivity of the electrode to dopamine in vitro before and after
insertion in (rat) brain tissue for 30 minutes, a period approxi-
mating the anticipated implantation time in human brain. The
electrochemical response to dopamine was linear with concentra-
tion and the sensitivity was not altered by brain implantation
(Figure 1c). Importantly, for the microsensor to have utility for
recordings in humans, it must be able to withstand sterilization.
Gas sterilization with ethylene oxide did not alter the sensitivity or
electrical noise level of the electrode (Figure 1d and 1e,
respectively) indicating maintained integrity of the electrochemical
surface and insulating seals.
We have developed and characterized an electrode assembly
intended for use in humans. The assembly is biocompatible [15],
can be sterilized without adverse effect on performance, and is
housed in a protective tube that is routinely used for clinical
neurosurgical applications and incorporates a reference electrode,
thus eliminating the need for an additional implant. The electrode
assembly shares the dimensions of an intraoperative neurophysio-
logical electrode conferring compatibility with the stereotactic frame
and manipulators used for the clinically-required neurosurgical
procedures; and can be used with a laptop-based data-acquisition
system that can be brought into an operating room. The
microsensor shares the electrochemical properties of existing
electrodes that are capable of detecting sub-second dopamine
release in the nanomolar range [10,15]. Together, these data
demonstrate that our instrumentation is safe (see below), compatible
with the neurosurgical environment and capable of sub-second
dopamine detection at physiological levels, satisfying our criteria for
a suitable methodology for in vivo neurochemical recording in
humans.
Next, we tested our electrode in a single human subject using
procedures approved by Baylor College of Medicine’s Institutional
Review Board. This proof-of-principle demonstration was con-
ducted in a consenting patient (MH), who suffered from late-stage
Parkinson’s disease and was undergoing elective surgery for DBS-
electrode implantation into the subthalamic nucleus. On the day
of surgery, MH was not medicated with levodopa. Following
routine intraoperative electrophysiology recording for functional
mapping of the DBS target site, the carbon-fiber microelectrode
assembly was placed in MH’s right caudate nucleus at
x = 19.18 mm, y= 9.13 mm, and z= 18.28 mm from the mid-
commissural point. This target was afforded due to the proximity
of the target location to the trajectory of the planned DBS
electrode insertion path. During insertion, the carbon fiber
electrode was retracted in the protective tube and advanced into
the brain for final placement. The subject then engaged in a
behavioral task [16] (see Methods S1) where the current value and
recent history of a stock market was graphically represented on a
laptop monitor. The subject chose the proportion of a portfolio
(initially valued at $100) to be invested in the stock market. These
decisions were submitted by pushing buttons on handheld
response devices. Following the submission of each decision, the
market was updated. The final value of the portfolio determined
the subject’s compensation. The subject had no prior knowledge of
these markets, nor had any direct experience in stock-market
trading. Throughout performance of this task, we monitored
dopamine release using fast-scan cyclic voltammetry at the carbon-
fiber microelectrode assembly with a sampling rate of 10 Hz. We
observed changes in the voltammetric signal that were consistent
with fluctuations in dopamine concentration as indicated by linear
regression analysis with a dopamine template obtained from the
rat brain (e.g., Figure 1f inset). Furthermore, using principle
component regression with a training set obtained in rats [19–21]
we predicted the value of the voltammetric signal attributable to
dopamine (Figure 1f). In a preliminary assessment, we tested for
correlation between this signal and pertinent behavioral indices
(Figure S1). A strong correlation was observed between the
dopamine signal and the market value throughout the sequential-
investment task (r2 = 0.549, p,0.000001). Furthermore, when
these variables were normalized to their own standard deviations
(z-scored), the linear regression slope was 0.91 indicating a near-
unity relationship in these variables. Surprisingly, the slope of the
dopamine signal over a period five seconds prior to a market price
update correlated with subsequent market returns (r2 = 0.156,
slope = 0.99, p = 0.0000482, n = 100 choices) demonstrating that it
is a significant predictor of future market activity. To test the
capacity of this prediction, we constructed a trading model based
on the fluctuations in the dopamine signal leading up to the
pathway in vivo recorded at conventional voltammetric electrodes or human electrode assembly (referenced to Ag/AgCl or stainless steel
respectively; r2 = 0.934, p,0.0001, n = 3). The inset shows the average electrochemical signature at the maximum response (r2 = 0.887, p,0.0001). (c)
Linear responses (vertical axis: peak oxidative currents for dopamine) of sterilized electrode responses to known concentrations of dopamine (62.5,
125, 250, 500 and 1000 nM) before (r2.0.987, p,0.001) and after (r2.0.997, p,0.0001) implantation in brain tissue. Data are mean 6 SEM, n = 3. (d)
Electrode sensitivity and (e) root-mean-square (RMS) noise is unchanged by gas sterilization with ethylene oxide (p.0.75 and p.0.65, paired t-test).
Data are expressed as mean 6 SEM, n = 7. (f) Voltammetric signals measured at electrode implanted in the patient’s right caudate: (left) sub-second
changes and (right) changes over several seconds. Changes in electrochemical current are measured at the peak oxidation potential for dopamine
(+0.65–0.75 V). Insets show cyclic voltammograms from the patient’s brain (black trace) compared to a standard reference cyclic voltammogram for
dopamine (dashed red trace; r2 = 0.75 (left) and r2 = 0.765 (right), p,0.0001 for both). These cyclic voltammograms were measured at the time points
indicated by the black arrowheads in the lower panels. The lower panels show two-dimensional plots with electrochemical current (nA, pseudo color,
see color bar to the right) plotted against time (horizontal-axis) and applied potential (vertical-axis).
doi:10.1371/journal.pone.0023291.g001
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market price updates, which invested 100% (all in) when the
dopamine slope was positive and 0% (all out) when the slope was
negative. Over the 5 markets played, this trader model earned
202 points (a gain of 175%), more than two times the amount
earned by the subject’s expressed behavior. These data demon-
strate that the information encoded in the dopamine signal of this
patient is potentially useful for economic decision making.
We have demonstrated the use of existing electrochemical
methods [8,9,10,15,19–21] – modified for compatibility with the
human brain and existing neurosurgical equipment – to measure
sub-second dopamine release in human striatum. It is important
that such technology be safe for human subjects. Our modifica-
tions adapted the electrochemical probe to the DBS electrode
implantation apparatus, thus the majority of the brain tissue
affected by the procedure was not different from that of the typical
surgical procedure. The tip of the carbon fiber probe is
significantly smaller that the sharp tungsten electrodes used to
functionally map the region and the DBS electrode that is left in
place for therapeutic outcome. Measurements recorded during
implantation demonstrated that the tip of the carbon fiber
electrode remained intact during the implantation procedure as
expected. From all accounts of the neurosurgeon and the surgical
staff, the placement of the DBS electrode, its intra-operative
efficacy, and post-operative efficacy were unaffected by our
procedure. The patient recovered as expected and received
therapeutic benefits from the DBS electrode well within the
expected range of efficacy. To our knowledge the procedure had
no adverse effects on the patients comfort or clinical outcome. The
present work and the recently reported measurement of human
substantia nigra neuron activity in Parkinson’s disease patients
[14] suggest that dopamine neuron activity and dopamine release
can be investigated in humans with a depleted dopamine system.
In summary, we have demonstrated the first in situ measure-
ments of dopamine release in a human brain; and have generated
preliminary evidence that dopamine release can be tracked and
investigated in the context of human decision-making behavior.
This methodological demonstration opens the door to future
investigations utilizing sub-second chemical measurements in the
human brain, which should yield important insights into the role
of dopamine signaling in human decision-making.
Methods
All of the work presented here was performed under the
approval of the University of Washington’s Institutional Animal
Care and Use Committee (rodent work: 4073-1) and Baylor
College of Medicine’s Institutional Review Board (human work:
H-24018). All procedures conform to the ethical principles
outlined in the Declaration of Helsinki. Baylor College of
Medicine’s Institution Review Board approved this study in
humans and written informed consent was obtained from the
patient. Detailed methods of all procedures are available in the
supplementary online material at http://www.plosone.org.
Supporting Information
Figure S1 Dopamine release in the caudate tracks the
market price during the sequential investment task. (a)
Sequential investment task. For each decision in the game the
subject is presented three pieces of information: (1) market trace
(red), (2) portfolio value (bottom left, ‘‘139’’ in this example) and
(3) the most recent fractional change in portfolio value (bottom
right, ‘‘223.92%’’ in this example). The vertical grey bar (middle)
is toggled by the subject to determine how much of one’s own
portfolio to invest in 10% increments (range= 0%–100%; ‘‘50’’ %
is shown here). (b) (left) Representative market (magenta trace:
normalized market value, N= 20 investment decisions) and
corresponding dopamine measurement (black trace: normalized
DA response in human caudate, 10 Hz sampling). Scale bar:
normalized units (s=1 standard deviation) along the vertical axis
and time (seconds) along the horizontal axis. Linear regression of
the dopamine response on to the market price shows a significant
correlation: p,0.000001; regression slope = 0.91; and r2 = 0.549,
N= 100 decisions. (middle) Scatter plot of the dopamine slope
(5 seconds prior to market update) and market returns along with
the fitted regression line. (slope= 0.99; p = 0.0000482, r2 = 0.155,
N= 100 decisions). (right) Bar plot comparing the performance of
two agents playing the investment task: two agents are compared:
patient ‘‘MH’’ and an agent modeled after the dopamine signal
(DA). (c) Cyclic voltammograms are measured once every 100 ms
in the human striatum. At each data point, a principal components
regression based model (Heien et al., 2005) is used to derive the
dopaminergic contribution to the measured signal. Here Q-values
(Qt) provide a measure of the unaccounted residual variance once
the PCR-model is applied. Instances where Qt surpasses an
experimentally determined Q-threshold (Qs) are plotted here
(‘‘+Qt’’, magenta data points) below the predicted dopamine
(black) and known market value (blue) traces. By this analysis
any dopamine data point accompanied by a magenta point is
predicted from a cyclic voltammogram that has a significant
amount of unaccounted for residual variance given the PCR
model used.
(TIFF)
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